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The forced oscillation technique (FOT) can be used to determine airway hyperresponsiveness,
but the cut-points for changes in respiratory system conductance (Grs) and reactance (Xrs)
that define a positive mannitol challenge are not known. Furthermore, the effects of changes
in lung volume on these cut-points or on the repeatability of the test are unknown.
In 15 non-asthmatic and 52 asthmatic subjects, response to mannitol challenge was
measured by Grs and Xrs, using FOT, and by FEV1. The FOT variables were adjusted for inspi-
ratory capacity (IC) at each dose. Dose response slope (DRS) was used in receiver operator
characteristic (ROC) analysis to compare the ability of adjusted and unadjusted DRSGrs and
DRSXrs to detect a positive challenge, defined as PD15FEV1 635 mg mannitol.
Mannitol challenges were positive in 32 asthmatic and 2 non-asthmatic subjects. Both
DRSGrs and DRSXrs detected positive challenges (p < 0.0001 for both), and this was not altered
by adjustment for IC for either DRSGrs (p Z 0.21) or DRSXrs (p Z 0.90). FOT cut-points for
a positive challenge were 27% fall in Grs or 0.93 cm H2O/L/s decrease in Xrs at 635 mg. Repeat-
ability of DRSGrs (2.01 doubling doses) and DRSXrs (1.95dd) was comparable with DRSFEV1
(1.67dd) and was not improved by adjustment for IC.
Grs and Xrs, measured by FOT, provide a sensitive, repeatable measure of response to
mannitol challenge. Adjusting for lung volume does not alter the ability of these variables
to detect a positive response or the repeatability of the measurement.
ª 2010 Elsevier Ltd. All rights reserved.s provided by Pharmaxis Ltd.
stitute of Medical Research, PO Box M77, Missenden Rd, NSW 2050, Australia. Tel.: þ61 2 9114 0403;
syd.edu.au (M.A. McClean).
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Airway hyperresponsiveness (AHR), a characteristic of
asthma, can be determined by bronchial challenge.
Mannitol, a naturally occurring sugar alcohol, is approved
for use in dry powder form as a bronchial challenge agent,
with a high specificity for the assessment of asthma.1,2
Clinically, mannitol is used to diagnose asthmatic adults
and children,1,3,4 is highly reproducible in children with
moderate to severe asthma on inhaled corticosteroid
treatment (ICS)5 and in asthmatic subjects taking ICS, AHR
to mannitol is comparable with AHR to both histamine and
methacholine.1,6 AHR to mannitol reflects the degree of
airway inflammation in steroid-naı¨ve asthmatic subjects7
and can identify inflammatory subtypes in asthma.8
Steroid responsiveness in mild to moderately severe
chronic obstructive pulmonary disease (COPD) can be pre-
dicted by AHR to mannitol.9 Therefore the use of mannitol
in bronchial challenge is a potentially useful tool for the
diagnosis and management of airway disease, which may be
applicable in clinical care.
Response to bronchial challenge is usually measured by
spirometry using the forced expiratory volume in 1 s (FEV1).
Spirometry is the standard measure of airway calibre but
being effort dependent, it requires full cooperation and
sub-maximal efforts at any stage of the bronchial challenge
result in the test being uninterpretable.10 The forced
oscillation technique (FOT), which is measured during tidal
breathing, may be easier for patients to perform than
spirometry in a primary care setting. The FOT requires
minimal cooperation and has been shown to be suitable in
measuring pulmonary function in populations that may have
difficulty performing spirometry, such as COPD patients and
children.11e13 The FOT provides measures of respiratory
system conductance (Grs), which reflect airway calibre,
and of respiratory system reactance (Xrs), which reflects
both the elastic and inertial properties of the airways.
During bronchial challenges with aerosols of histamine or
methacholine in children, response measured by FOT is
highly sensitive but only moderately specific for bronchial
responses measured by FEV1.
12,13 Previous studies have
shown a strong correlation between a 20% fall in FEV1
(pD20FEV1) and a 40% increase in respiratory system resis-
tance at 6 Hz (pD40Rrs6).
14,15 However, cut-points that have
a high sensitivity and specificity for a positive test defined
by PD20FEV1 may require a much greater change.
16
The utility of FOT for measuring the response to mannitol
challenge has not been assessed, and cannot be assumed
from studies of FOT in challenges with histamine or meth-
acholine. Mannitol differs from histamine and methacholine
challenges in both mode of delivery and action, being a dry
powder rather than aerosol, and having an indirect rather
than a direct effect on airway smooth muscle. Since these
differences could alter airway responses, particularly in the
peripheral airways, the cut-points for Grs and Xrs may differ
from those defined for aqueous direct challenge agents.
Response to mannitol is defined by a 15% fall in FEV1,
1 rather
than a 20% fall in FEV1 used for aqueous direct challenge
agents, which would also suggest that different FOT cut-
points are needed. Furthermore, the effect of hyperinfla-
tion, occurring during bronchial challenge, on FOT variables,which are volume dependent, has not been assessed in any
previous studies.
The aim of this study was to determine the utility of FOT
as a measure of response to mannitol challenge. We
calculated the sensitivity and specificity of FOT responses,
measured by Grs and Xrs, for a positive mannitol challenge
defined by a 15% fall in FEV1 and used values with the
highest combination of sensitivity and specificity to define
cut-points for a positive test based on the FOT responses. In
addition, we compared the repeatability of the responses
measured by FOT and FEV1, and determined the effect of
adjusting the FOT variables for changes in lung volume,
measured by changes in inspiratory capacity during chal-
lenge, on the sensitivity and specificity and the repeat-
ability of the FOT responses.
Methods
Subjects
Asthmatic and healthy non-asthmatic subjects, aged
between 17 and 70 years, were recruited from the staff and
volunteer database at the Woolcock Institute of Medical
Research and the Department of Respiratory Medicine,
Royal North Shore Hospital, and by advertising throughout
the University of Sydney.
Asthmatic subjects were eligible to participate if they
had a previous diagnosis of asthma from a physician, had
FEV1 greater than 60% predicted or 1.4 L, and were able to
withhold medication. Healthy non-asthmatic subjects had
no history or symptoms of respiratory disease, or use of
asthma medication. Subjects were excluded if they were
current smokers or were ex-smokers with a 10 pack years
smoking history or had a respiratory tract infection within
the last four weeks.
Written informedconsentwas obtained fromeach subject
before they undertook the study. The experimental protocol
was approved by the South West Sydney Area Health Service
Human Research Ethics Committee (Protocol no. X06-0129).
Experimental protocol
Prior to their laboratory visits subjects withheld short-
acting b2-agonist for 6 h, long-acting b2-agonist for 24 h and
inhaled corticosteroids (ICS) for 24 h. In addition, subjects
were asked to abstain from caffeine and strenuous exercise
on the day of the study. At the initial visit subjects were
screened using baseline lung function and a clinical ques-
tionnaire, to obtain details of asthma symptoms, medica-
tion use, smoking history and medical history. In addition,
asthmatic subjects completed the Juniper Asthma Control
Questionnaire (ACQ).17 Atopic status was defined by skin
prick tests using 16 common aeroallergens (cockroach,
house dust, Dermatophagoides farinae, Dermatophagoides
pteronyssinus, cat, dog, horse hair, feather, ragweed,
plantain, timothy grass, rye grass, aspergillus, alter-
naria).18 Exhaled nitric oxide (eNO) were measured using an
offline technique, according to American Thoracic Society
(ATS) criteria19, at an expiratory flow rate of 200 ml/s, as
previously described.20
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and repeated at a second visit within two weeks. On each
occasion, response to mannitol challenge was measured
using both FOT and spirometry. To do this, FOT measure-
ments commenced immediately after administration of the
mannitol, and continued for 40 s tidal breathing, after
which each subject took two or more breaths to total lung
capacity (TLC), to measure inspiratory capacity (IC).
Spirometry was then measured in the standard way, within
90 s of mannitol administration.
Mannitol challenge
Mannitol challenges were performed according to the
manufacturer’s specifications (Pharmaxis Ltd, Frenchs
Forest, NSW, Australia). Briefly, subjects inhaled increasing
doses of encapsulated dry powder mannitol through an
Osmohaler followed by a 5 s breath hold in doses ranging
from 5 to 635 mg of mannitol. An empty capsule was used as
the control from which the percentage fall in FEV1 during
the mannitol challenge was calculated. The challenge was
stopped if the FEV1 fell by 20% from the control FEV1 or
a cumulative dose of 635 mg was administered. The
provocative dose of mannitol causing a 15% fall in FEV1
(PD15FEV1) was calculated by linear interpolation. A posi-
tive challenge was defined as PD15FEV1 635 mg based on
results in healthy non-asthmatic subjects.1
Spirometry
Spirometric function was measured according to ATS
criteria using Spirocard (QRS Diagnostics, Plymouth, MN,
USA) that was calibrated daily. Spirometry was measured at
baseline and at each dose of the mannitol challenge
immediately following the FOT measurement (60e90 s after
inhaled mannitol dose). The highest FEV1 was recorded
from two readings which were within 0.1 L.21
Forced oscillation technique (FOT)
Respiratory system resistance (Rrs) and reactance (Xrs)
were measured using the FOT at an oscillation frequency of
6 Hz, at baseline and after each dose of mannitol before
spirometry. Subjects breathed tidally for 40 s on the FOT
followed by a slow deep inspiration to TLC with a passive
relaxation back to functional residual capacity (FRC) and
a return to tidal breathing. The deep inspiration manoeuvre
was repeated until two inspiratory capacity (IC) measure-
ments were obtained that were within 60 ml or 5% of each
other. The larger of the two IC measurements was
recorded.22
The FOT measurements were made using a device
developed in house, and analysed using customised soft-
ware, as previously described.23,24 The analysis automati-
cally excludes any erroneous and extreme values of Rrs
from any subsequent processing, and provides continuous
outputs of Rrs and volume over the recording period. Mean
Grs, as the reciprocal of Rrs, and mean Xrs were calculated
over 40 s of tidal breathing for each dose of mannitol.
Changes in resting lung volume were determined by
changes in IC measured by the volume trace on the FOT.Mean Grs and mean Xrs were multiplied by IC as a volume-
adjusted Grs (GrsxIC) and Xrs (XrsxIC) at each dose.
Data analysis
The primary outcome variable for the response to mannitol
challenge was the dose response slope (DRS),25 which was
calculated as the two-point slope by dividing the change in
each of the respiratory function variables by the cumulative
dose of mannitol. This variable has also been termed
response dose ratio (RDR) in previous mannitol challenges.2
A DRS was calculated for each subject for each mannitol
challenge, using the percent change from baseline, for FEV1
and Grs, and the absolute change from baseline for Xrs. The
DRS values for Grs, Xrs and FEV1 were all log-normally
distributed. Because some non-responsive subjects had
small improvements in some of these variables at the end of
the challenge (i.e. zero or negative responses) a constant
was added to the raw DRS to permit log transformation. The
constants were 0.02 for FEV1, 0.05 for Grs and 0.0005 for
Xrs. Values for DRS were also calculated for Grs and Xrs,
after adjustment for IC and the same constants were used
to permit log transformation.
Summary data are expressed as means and standard
deviations for normally distributed variables, and as
geometric means and 95% confidence intervals for the log-
normally distributed variables, DRS and eNO. Between
group comparisons were made using unpaired Student
t-tests. Summary data for ICS dose and ACQ score are
expressed as medians and interquartile ranges, with
between group comparisons made using the ManneWhitney
U test. For categorical variables, data are expressed as
number and percent of group, and analysed by the Chi-
squared test.
Repeatability of the DRS values was measured by 95%
limits of agreement using the method of Bland & Altman,26
and converted to doubling dose units for ease of interpre-
tation. Intra-class correlation coefficients were also calcu-
lated as an index of the within subject variability.
Receiver operator characteristic (ROC) curves were
plotted using data from the initial visit. Comparisons of the
area under the curve between DRSGrs and DRSGrsxIC and
between DRSXrs and DRSXrsxIC were used to determine the
effect of adjustment for lung volume on the ability of the
FOT variables to detect a positive response. The FOT cut-
points to define a positive challenge comparable with
PD15FEV1 were calculated from the DRS values with the
highest combination of sensitivity and specificity.Results
Subject characteristics and airway function
A total of 67 subjects, including 15 non-asthmatic and 52
asthmatic subjects were studied (Table 1). Non-asthmatic
subjects had normal baseline spirometry. All asthmatic
subjects had baseline FEV1 >60% predicted and were well-
controlled as defined by the Global Initiative for Asthma
(GINA).27 Asthmatic subjects were more likely to be atopic
and had significantly higher eNO (p Z 0.004) than the non-
Table 1 Subject characteristics of non-asthmatic and asthmatic subjects. Values are mean  standard deviation (SD),
geometric mean (95%CI) or N (%).
Non-asthmatic Asthmatic p value
N 15 52 e
Male/Female 5/10 26/26 e
Age (range) 34.0 (22e56) 39.4 (18e66) e
Atopic 8 (53%) 43 (83%) e
eNO (ppb) 8.0 (6.3e10.2) 14.6 (12.1e17.7) 0.004
FEV1 (% pred) 104  14.4 87  13.0 0.0001
FVC (% pred) 108  18.5 97  13.2 0.01
FEV1/FVC 82.3  5.9 75.7  9.2 0.007
CI Z confidence intervals; eNO Z exhaled nitric oxide.
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mines or leukotriene receptor antagonists.
Mannitol challenge
Mannitol challenge was undertaken in all 67 subjects, and
15 non-asthmatic and 44 asthmatic subjects underwent
repeat testing. Two non-asthmatic and 32 asthmatic
subjects had a positive response to mannitol (15% fall in
FEV1). At the initial visit, asthmatic subjects who responded
to mannitol had higher eNO and were more likely to be
atopic than the asthmatic subjects who were negative to
mannitol (Table 2). Airway obstruction, the use of ICS and
the ACQ did not differ significantly between the two asth-
matic groups.
Comparison of conductance and reactance dose
response slope
DRSFEV1 was significantly correlated with both DRSGrs
(r Z 0.78, p < 0.0001) and DRSXrs (r Z 0.75, p < 0.0001).
Fig. 1 shows the relationship between DRSFEV1 and DRSGrs
and between DRSFEV1 and DRSXrs. The vertical line on each
graph shows the cut-point for a positive mannitol challengeTable 2 Characteristics of asthmatics with and without a po
mean  standard deviation (SD), geometric mean (95%CI) or N (%
Asthmatics Positive to mannitol
N 32
Male/Female 17/15
Age 39.3  16.5
eNO (ppb) 17.9 (14.2e22.7)
Atopic 30 (94%)
FEV1 (% pred) 86.6  12.2
FVC (% pred) 98.3  13.7
FEV1/FVC 74.1  8.2
Current ICS use 26 (81%)
aCurrent ICS dose (mg/day) 400 (250e575)
aACQ Score 0.86 (0.40e1.43)
Good control (ACQ <0.75) 15 (47%)
Poor control (ACQ >1.50) 5 (16%)
CI Z confidence intervals; eNO Z exhaled nitric oxide; ICS Z
IQR Z interquartile range.
a median (IQR).(PD15FEV1) for DRSFEV1. The horizontal line on each graph
shows the cut-points for DRSGrs and DRSXrs calculated from
the ROC curves. Fig. 2 shows the ROC curves for DRSGrs and
DRSXrs. Both variables had highly significant ability to
detect positive challenges defined by FEV1 (p < 0.0001 for
both DRSGrs and DRSXrs). However the difference in the
area under the ROC curve (AUC) approached significance
(0.098; p Z 0.07) suggesting that DRSXrs had slightly
better discriminatory power than DRSGrs for detecting
a positive mannitol challenge. The cut-points and the
sensitivity and specificity for a positive mannitol challenge
are shown in Table 3 (Fig. 3).
The repeatability of DRSGrs and DRSXrs was comparable
with DRSFEV1 for both the 95% limits of agreement and the
intra-class correlation coefficient (Table 4). When the
analysis was limited to those subjects with a positive
challenge, the repeatability of the test measured by FEV1
or Grs was slightly worse than for the group as a whole.
Adjustment for lung volume
Mannitol challenge induced mild hyperinflation in asthmatic
subjects with a positive response to challenge (mean
decrease in IC Z 12.1  3.6%), which was significantlysitive response to mannitol at the initial visit. Values are
).
Negative to mannitol p value
20 e
9/11 e
39.7  13.9 0.93
10.5 (8.0e14.0) 0.006
13 (65%) 0.02
88.5  13.8 0.60
95.9  12.3 0.51






inhaled corticosteroids; ACQ Z asthma control questionnaire;
Figure 1 Dose response slopes (DRS) showing the relationship at 6 Hz between A) DRSFEV1 and DRSGrs, B) DRSFEV1 and DRSXrs at
the initial visit. Z cut-points for a positive mannitol challenge calculated from the ROC curves (vertical Z DRSFEV1, horizon-
tal Z DRSGrs and DRSXrs).
Forced oscillation technique 537greater than in the asthmatic subjects with a negative
challenge (4.85  4.64%; p Z 0.02) and in non-asthmatics
subjects (2.14  3.72%; p < 0.001). However in all
subjects, adjusting Grs or Xrs for IC during mannitol chal-
lenge did not significantly alter the AUC of the ROC curves
for Grs (p Z 0.21) or Xrs (p Z 0.90) or the DRS cut-points
(Table 3) and did not improve the repeatability of the
responses measured by Grs and Xrs (Table 4).
Discussion
This study has shown that a positive response to a mannitol
challenge can be measured using FOT producing values for
DRS that correlate closely to responses measured by FEV1. A
positive mannitol challenge, defined by PD15FEV1, was
detected by both Grs and Xrs, with cut-points of 27% fall inFigure 2 Comparison of ROC curves for DRSGrs (>) and
DRSXrs (-) at the initial visit. Z no discrimination.Grs or 0.93 cm H2O/L/s fall in Xrs, at 635 mg mannitol. This
study has also shown that adjusting Grs and Xrs for lung
volume does not alter the sensitivity and specificity of
these variables for detecting a positive response. The
repeatability of DRS values for the FOT variables was similar
to DRSFEV1 and was not improved by adjusting for changes
in lung volume during the challenge test. These findings
suggest that FOT is a valid and reproducible method for
detecting AHR to mannitol, even in subjects who hyper-
inflate during challenge.
The cut-points for the FOT reported in this study define
a positive response to mannitol with a high degree of both
sensitivity and specificity. To define the cut-points for the
FOT that correspond to a positive test, the response to
mannitol was analysed using DRS as it provides a continuous
variable for all subjects and avoids censoring data from
non-responsive subjects. Clearly it is essential to include
both responsive and non-responsive subjects in a study to
define cut-points that distinguish responders from non-
responders. Values for DRSFEV1 and PD20FEV1 are highly
correlated and provide qualitatively identical information
about airway responsiveness.16,28
This study has demonstrated the utility of FOT for
bronchial challenge tests by demonstrating its ability to
detect positive tests defined by FEV1. Previous studies in
airway disease have shown that FOT variables are a more
sensitive index for detecting changes in bronchial calibre
than FEV1,
29e32 but this was not addressed in the present
study. The strong association between airway responsive-
ness measured by FOT and spirometry in the present study
is consistent with findings from previous studies in both
adults and children.12,14,16,29,30,33 A similar association was
also found in a recent study of impulse oscillometry during
mannitol challenge in children.34 Our study protocol, in
which both FOT variables and FEV1 were measured during
the same challenge test, was similar to that used in
previous studies that compared FOT and FEV1 during
methacholine or histamine challenge.14,30 The onset of the
response to mannitol is very rapid and peaks between 30
and 90 s and declines slowly thereafter, which allows
sufficient time to measure both the FOT and FEV1 variables.
Our FOT protocol also included at least two maximal inha-
lations to measure IC. It is unlikely that these manoeuvres
had any additional influence on the PD15FEV1, beyond that
of the multiple deep inspirations that are a standard part of
Figure 3 ROC curves showing the ability to detect a positive mannitol challenge for A) Grs (>) and GrsxIC (-) and B) Xrs (>) and
XrsxIC (-) at the initial visit. Z no discrimination.
538 M.A. McClean et al.measuring reproducible FEV1 values during challenge.
However, deep inspirations have a profound modulatory
effect on the response of airway smooth muscle,35 and thus
the cut-points defined in the present study, and in previous
studies that have measured both FOT and FEV1 during the
same challenge test, cannot be applied to challenge tests
that do not incorporate deep inspirations into the protocol.
Hyperinflation during challenge can affect Grs and Xrs
measurements because of their known volume dependence.
The magnitude of hyperinflation during a standard direct
challenge depends on the magnitude of change in FEV1, but
changes in IC observed in subjectswith apositive challenge in
the present study are similar to thosemeasured previously in
subjects with mild asthma at 20% fall in FEV1.
36 Change in IC
during challenge is widely accepted as a marker of hyperin-
flation during challenge.36,37 We found that adjusting the
FOTvariables for changes in ICdid not affect the ability of the
FOT to detect a positive mannitol test since there were no
significant differences in the area under the ROC curve
between adjusted and unadjusted variables. Furthermore,
adjusting the FOT variables for hyperinflation did not alter
the repeatability of the DRS measurements. The absence of
any effect of hyperinflation on the cut-point for DRSGrs is not
surprising since hyperinflation only affected the change in
Grs in subjects with a positive challenge, the majority ofTable 3 Area under the ROC curve (AUC) for FOT variables dete
PD15FEV1 635 mg mannitol, and the log DRS cut-points and sens
Grs GrsxIC
AUC 0.84 (0.73e0.95) 0.89 (0.80
log DRS cut-point 1.04 1.03
Change at 635 mg 26.6% fall 27.3% fall
Sensitivity 77 87
Specificity 88 88
DRS Z dose response slope; Grs Z respiratory system conductanc
Xrs Z respiratory system reactance; XrsxIC Z volume-adjusted res
parentheses are 95% confidence intervals.whom had DRS values above the cut-point. Since adjustment
for hyperinflation did not improve either the sensitivity and
specificity or the repeatability of the responses measured by
FOT, these findings suggest that there is no need to make the
difficult and highly effort dependent measurements of IC
during challenge in order to determine the presence of AHR
to mannitol. However, more pronounced hyperinflation may
modify DRS values in subjects with a positive response, and
further studies may be required to determine the clinical
importance of these effects.
There are very few previous reports of the repeatability
of outcome measures from challenge tests using FOT, and
the results vary between studies. One study15 found that
the repeatability of PC40Rrs was two-fold worse than
that for PC20FEV1 to carbachol, whereas another
38 found
that the repeatability of PD35Rrs was the similar to that for
PC20FEV1. In the present study the repeatability of the
mannitol challenge measured by FOT variables was similar
to the repeatability measured by FEV1 and was not affected
by hyperinflation. We also found that the repeatability of
DRSFEV1 was similar to the repeatability of PD15FEV1 for
mannitol challenge reported previously.1,5
Our findings are consistent with recent evidence that
response to mannitol challenge reflects the degree of
airway inflammation.7,8 The asthmatic subjects in thiscting subjects with a positive mannitol challenge, defined by
itivity and specificity derived from the ROC curves.
Xrs XrsxIC
e0.99) 0.89 (0.80e0.98) 0.92 (0.84e0.96)
2.71 2.53
0.93 cm H2O/L/s 1.54 cm H2O.s
87 97
88 84
e; GrsxIC Z volume-adjusted respiratory system conductance;
piratory system reactance; IC Z inspiratory capacity. Values in
Table 4 Repeatability of DRS values expressed as the 95% limits of agreement (LoA) in doubling dose (dd) units, and as the
intra-class correlation coefficient (ICC) in all subjects and in asthmatics with a positive mannitol challenge.
FEV1 Grs GrsxIC Xrs XrsxIC
All subjects
95% LoA (dd units) 1.67 2.01 2.01 1.95 2.67
ICC 0.87 0.74 0.78 0.88 0.83
Asthmatics with þ ve challenge
95% LoA (dd units) 2.23 2.34 2.15 2.07 2.66
ICC 0.74 0.68 0.79 0.86 0.82
DRS Z dose response slope; Grs Z respiratory system conductance; GrsxIC Z volume-adjusted respiratory system conductance;
Xrs Z respiratory system reactance; XrsxIC Z volume-adjusted respiratory system reactance; IC Z inspiratory capacity.
Forced oscillation technique 539study had well-controlled asthma according to the levels of
asthma control as defined by GINA27, but with a wide range
of responsiveness to mannitol challenge. Asthmatic
subjects with a positive challenge had similar ACQ scores
and ICS usage to the asthmatics with a negative challenge,
but asthmatic subjects with a positive challenge had higher
eNO, suggesting greater airway inflammation, and a higher
prevalence of atopy.
In summary, this study has shown that FOT can provide
a sensitive and repeatable measure of response to mannitol
challenge which is consistent with that obtained by spirom-
etry. Furthermore, adjustment for changes in lung volume
does not alter the sensitivity and specificity of the FOT
variables for detecting a positive response. The FOT is
a simplemeasurement that is non-invasive, requiresminimal
patient cooperation and is not effort dependent. Thus, it is
particularly suitable for use in bronchial challenge tests,
which would usually require repeated maximal forced
manoeuvres, and in patient populations, such as children and
older patients with airway obstruction, who find these
spirometric manoeuvres uncomfortable and difficult. This
study strongly supports a role for the FOT in bronchial chal-
lenge testing using mannitol in the clinical setting.
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